218 related articles for article (PubMed ID: 31146914)
1. Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest.
Jin Y; Ma D; Gramyk T; Guo C; Fang R; Ji H; Shi YG
Biochem Biophys Res Commun; 2019 Jul; 515(1):214-221. PubMed ID: 31146914
[TBL] [Abstract][Full Text] [Related]
2. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
[TBL] [Abstract][Full Text] [Related]
3. LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
Takagi S; Ishikawa Y; Mizutani A; Iwasaki S; Matsumoto S; Kamada Y; Nomura T; Nakamura K
Cancer Res; 2017 Sep; 77(17):4652-4662. PubMed ID: 28667074
[TBL] [Abstract][Full Text] [Related]
4. The small cell lung cancer-specific isoform of RE1-silencing transcription factor (REST) is regulated by neural-specific Ser/Arg repeat-related protein of 100 kDa (nSR100).
Shimojo M; Shudo Y; Ikeda M; Kobashi T; Ito S
Mol Cancer Res; 2013 Oct; 11(10):1258-68. PubMed ID: 23928058
[TBL] [Abstract][Full Text] [Related]
5. Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1.
Chen HY; Durmaz YT; Li Y; Sabet AH; Vajdi A; Denize T; Walton E; Laimon YN; Doench JG; Mahadevan NR; Losman JA; Barbie DA; Tolstorukov MY; Rudin CM; Sen T; Signoretti S; Oser MG
Nat Commun; 2022 Aug; 13(1):4998. PubMed ID: 36008402
[TBL] [Abstract][Full Text] [Related]
6. Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4-driven transcriptional state.
Yan W; Chung CY; Xie T; Ozeck M; Nichols TC; Frey J; Udyavar AR; Sharma S; Paul TA
Mol Oncol; 2022 Mar; 16(6):1309-1328. PubMed ID: 34669238
[TBL] [Abstract][Full Text] [Related]
7. KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells.
Kong L; Zhang P; Li W; Yang Y; Tian Y; Wang X; Chen S; Yang Y; Huang T; Zhao T; Tang L; Su B; Li F; Liu XS; Zhang F
Oncotarget; 2016 May; 7(19):27959-74. PubMed ID: 27058897
[TBL] [Abstract][Full Text] [Related]
8. Lysine‑specific demethylase 2 contributes to the proliferation of small cell lung cancer by regulating the expression of TFPI‑2.
Cao Y; Guo C; Yin Y; Li X; Zhou L
Mol Med Rep; 2018 Jul; 18(1):733-740. PubMed ID: 29845195
[TBL] [Abstract][Full Text] [Related]
9. Bmi1 regulates cell fate via tumor suppressor WWOX repression in small-cell lung cancer cells.
Kimura M; Takenobu H; Akita N; Nakazawa A; Ochiai H; Shimozato O; Fujimura Y; Koseki H; Yoshino I; Kimura H; Nakagawara A; Kamijo T
Cancer Sci; 2011 May; 102(5):983-90. PubMed ID: 21276135
[TBL] [Abstract][Full Text] [Related]
10. Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC.
Nguyen EM; Taniguchi H; Chan JM; Zhan YA; Chen X; Qiu J; de Stanchina E; Allaj V; Shah NS; Uddin F; Manoj P; Liu M; Cai SF; Levine R; Quintanal-Villalonga Á; Sen T; Chow A; Rudin CM
J Thorac Oncol; 2022 Aug; 17(8):1014-1031. PubMed ID: 35691495
[TBL] [Abstract][Full Text] [Related]
11. Suppression of HELLS by miR-451a represses mTOR pathway to hinder aggressiveness of SCLC.
Cui J; Wang J; Shen Y; Lin D
Genes Genomics; 2021 Feb; 43(2):105-114. PubMed ID: 33460027
[TBL] [Abstract][Full Text] [Related]
12. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer.
Huang J; Cao D; Sha J; Zhu X; Han S
Biochem Biophys Res Commun; 2019 Jun; 514(3):853-860. PubMed ID: 31079917
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the NRSF/REST gene by methylation and CREB affects the cellular phenotype of small-cell lung cancer.
Kreisler A; Strissel PL; Strick R; Neumann SB; Schumacher U; Becker CM
Oncogene; 2010 Oct; 29(43):5828-38. PubMed ID: 20697351
[TBL] [Abstract][Full Text] [Related]
14. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets.
Krushkal J; Silvers T; Reinhold WC; Sonkin D; Vural S; Connelly J; Varma S; Meltzer PS; Kunkel M; Rapisarda A; Evans D; Pommier Y; Teicher BA
Clin Epigenetics; 2020 Jun; 12(1):93. PubMed ID: 32586373
[TBL] [Abstract][Full Text] [Related]
15. Distinct transcriptional programs of SOX2 in different types of small cell lung cancers.
Tenjin Y; Matsuura K; Kudoh S; Usuki S; Yamada T; Matsuo A; Sato Y; Saito H; Fujino K; Wakimoto J; Ichimura T; Kohrogi H; Sakagami T; Niwa H; Ito T
Lab Invest; 2020 Dec; 100(12):1575-1588. PubMed ID: 32801334
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer.
Hokari S; Tamura Y; Kaneda A; Katsura A; Morikawa M; Murai F; Ehata S; Tsutsumi S; Ishikawa Y; Aburatani H; Kikuchi T; Miyazono K; Koinuma D
Mol Oncol; 2020 Feb; 14(2):277-293. PubMed ID: 31782890
[TBL] [Abstract][Full Text] [Related]
17. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
Mohammad HP; Smitheman KN; Kamat CD; Soong D; Federowicz KE; Van Aller GS; Schneck JL; Carson JD; Liu Y; Butticello M; Bonnette WG; Gorman SA; Degenhardt Y; Bai Y; McCabe MT; Pappalardi MB; Kasparec J; Tian X; McNulty KC; Rouse M; McDevitt P; Ho T; Crouthamel M; Hart TK; Concha NO; McHugh CF; Miller WH; Dhanak D; Tummino PJ; Carpenter CL; Johnson NW; Hann CL; Kruger RG
Cancer Cell; 2015 Jul; 28(1):57-69. PubMed ID: 26175415
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.
Pishas KI; Drenberg CD; Taslim C; Theisen ER; Johnson KM; Saund RS; Pop IL; Crompton BD; Lawlor ER; Tirode F; Mora J; Delattre O; Beckerle MC; Callen DF; Sharma S; Lessnick SL
Mol Cancer Ther; 2018 Sep; 17(9):1902-1916. PubMed ID: 29997151
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.
Venkata PP; Jayamohan S; He Y; Alejo S; Johnson JD; Palacios BE; Pratap UP; Chen Y; Liu Z; Zou Y; Lai Z; Suzuki T; Viswanadhapalli S; Weintraub ST; Palakurthi S; Valente PT; Tekmal RR; Kost ER; Vadlamudi RK; Sareddy GR
Cancer Lett; 2023 Oct; 575():216383. PubMed ID: 37714256
[TBL] [Abstract][Full Text] [Related]
20. FGFR1 Is Critical for RBL2 Loss-Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer.
Kim KB; Kim Y; Rivard CJ; Kim DW; Park KS
Cancer Res; 2020 Nov; 80(22):5051-5062. PubMed ID: 32973083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]